Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies.
- DOI
- 10.3389/fphar.2026.1822157
- Published
- 2026
- Container
- Frontiers in pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2026.1822157,
title = {Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies.},
author = {Ali LS and Mostafa MO and Alsharayiah D and Elkholy MA and Ahmed KA and El-Mansy AA and Sharfeldeen AERM and El Wakeel G and Badawy AA and Sulaiman AH and Ali EI and Alenazi MS and Alruwaili MM and Hamza E and Eldesoqui M},
year = {2026},
journal = {Frontiers in pharmacology},
doi = {10.3389/fphar.2026.1822157},
url = {https://doi.org/10.3389/fphar.2026.1822157}
}RIS
TY - JOUR TI - Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies. AU - Ali LS AU - Mostafa MO AU - Alsharayiah D AU - Elkholy MA AU - Ahmed KA AU - El-Mansy AA AU - Sharfeldeen AERM AU - El Wakeel G AU - Badawy AA AU - Sulaiman AH AU - Ali EI AU - Alenazi MS AU - Alruwaili MM AU - Hamza E AU - Eldesoqui M PY - 2026 JO - Frontiers in pharmacology DO - 10.3389/fphar.2026.1822157 UR - https://doi.org/10.3389/fphar.2026.1822157 ER -
APA
LS, A., MO, M., D, A., MA, E., KA, A., AA, E., AERM, S., G, E. W., AA, B., AH, S., EI, A., MS, A., MM, A., E, H., & M, E. (2026). Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1822157
Source records
- pubmed · retrieved 2026-09-26T11:21:40.598Z